| Literature DB >> 36092820 |
Sergio Pedraza-Arevalo1, Ana-Maria Cujba1, Mario Enrique Alvarez-Fallas1, Rocio Sancho2.
Abstract
Human induced pluripotent stem cells (hiPSCs) and organoids are important for modeling human development and disease in vitro. In this study, we describe a protocol to differentiate hiPSC toward pancreatic progenitor (PP) organoids and beta-like cells. We detail the expansion and seeding of hiPSC, PP differentiation, organoid expansion, and the differentiation of PP into beta cells. Upon differentiation, organoids contained beta, delta, and alpha cells. For complete details on the use and execution of this protocol, please refer to Cujba et al. (2022).Entities:
Keywords: Cell differentiation; Developmental biology; Metabolism; Organoids; Stem cells
Mesh:
Year: 2022 PMID: 36092820 PMCID: PMC9449863 DOI: 10.1016/j.xpro.2022.101656
Source DB: PubMed Journal: STAR Protoc ISSN: 2666-1667
Figure 1Differentiation summary
(A) Schematic diagram of hiPSCs differentiated toward definitive endoderm (DE), primitive gut tube (PGT), posterior foregut (PF) and pancreatic progenitors (PP), with the respective brightfield (B) images.
(C) Representative Immunofluorescence images at the iPSCs, DE and PP stages.
(D) Schematic diagram of PPs expanded as pancreatic organoids (PO) and differentiated towards beta-like cells, either in suspension or Matrigel aggregates, with the respective brightfield and immunofluorescence pictures (E).
Scale bars, 50 μm (B and C) and 100 μm (E).
Adapted from Cujba et al. (2022).
Figure 2Characterization of pancreatic progenitors (PP)
(A) Brightfield images of a hiPSC culture at high (left) and low (right) confluency, one day after splitting.
(B) Brightfield images of a healthy hiPSC culture with defined edges (left) and a differentiated unhealthy hiPSC culture with stromal-like morphologies and heterogenous cells (right).
(C) Immunofluorescence of hiPSC at the beginning of the differentiation, validated for expression of the pluripotency markers OCT4, NANOG, and SOX2.
(D) Immunofluorescence for DE markers SOX17 and pluripotent marker OCT4 at the DE stage, HNF1B at the PF stage, and PDX1, NKX6.1, and SOX9 at the PP stage.
(E) Example of a suboptimal differentiation characterized by few and low expressing PDX1, NKX6.1 and SOX9 positive cells at the PP stage. Scale bars, 50 μm (A, B, D and E) and 30 μm (C).
Adapted from Cujba et al. (2022).
Figure 4Characterization of endocrine cells at the final differentiation stage
(A) Brightfield picture of aggregates after 16 days of differentiation.
(B) Immunofluorescence for insulin, somatostatin and glucagon at the end of differentiation in aggregates.
(C) Brightfield picture of a dome of Matrigel after 16 days of differentiation.
(D) Immunofluorescence for insulin, somatostatin and glucagon at the end of differentiation using Matrigel. Scale bars, 100 μm (A and C) and 50 μm (B and D). Adapted from Cujba et al. (2022).
Figure 3Characterization of pancreatic organoids (PO)
(A) Brightfield images of pancreatic organoids growing at different time points after seeding.
(B) Immunofluorescence characterization of pancreatic organoids showing PDX1 and CK19 expression at various differentiation stages. Scale bars, 100 μm (A) and 50 μm (B).
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| Goat anti-SOX17 (1:200) | R&D | Cat#AF1924; RRID: |
| Mouse anti-OCT4 (1:300) | Santa Cruz | Cat#sc-5279; |
| Rabbit anti-NANOG (1:300) | Cell Signaling Technology | Cat#4903S; |
| Rabbit anti-PDX1 (1:300) | Cell Signaling Technology | Cat#5679; |
| Guinea pig anti-PDX1 (1:300) | Abcam | Cat#ab47308; |
| Mouse anti-NKX6.1 (1:400) | DSHB | Cat#F55A12; |
| Goat anti-SOX9 (1:300) | R&D | Cat#AF3075; |
| Guinea pig anti-insulin (1:300) | Dako | Cat#A0564; |
| Rabbit anti-somatostatin (1:300) | Dako | Cat#A0566; |
| Mouse anti-glucagon (1:300) | Abcam | Cat#ab10988; |
| Rat anti-CK19 (1:300) | DSHB | Cat#TROMA IIIc 10ea; |
| Donkey anti-mouse Alexa 647 (1:300) | Invitrogen | Cat#A31571; |
| Donkey anti-rabbit Alexa 488 (1:300) | Invitrogen | Cat#A21206; |
| Donkey anti-goat Alexa 647 (1:300) | Invitrogen | Cat#A21432; |
| Donkey anti-mouse Alexa 488 (1:300) | Invitrogen | Cat#A21202; |
| Goat anti-guinea pig Alexa 488 (1:300) | Invitrogen | Cat#A11073; |
| Donkey anti-rat Alexa 647 (1:300) | Invitrogen | Cat#A21472; |
| Ethylenediaminetetraacetic acid (EDTA) | Fisher Bioreagents | BP2482-500 |
| Accutase | BioLegend | 423201 |
| Matrigel Growth Factor Reduced (GFR) | Corning | 354230 |
| Vitronectin | STEMCELL Technologies | 7180 |
| HEPES | Thermo Fisher Scientific | 15630080 |
| Glutamax supplement | Thermo Fisher Scientific | 3505006 |
| Penicilin/Streptomycin | Thermo Fisher Scientific | 15140122 |
| A83-01 | Tocris | 2939 |
| Human FGF-10 | PeproTech | 100-26 |
| GastrinI | Sigma | SCP0151 |
| Mouse EGF | PeproTech | AF10015 |
| N-acetylcysteine | Sigma-Aldrich | A9165 |
| Nicotinamide | Sigma-Aldrich | N0636-100G |
| B-27 supplement | Thermo Fisher Scientifi | 17504044 |
| Noggin conditioned medium | This study | N/A |
| R-spondin conditioned medium | This study | N/A |
| Y-27631 | Adooq Bioscience | A11001 |
| TrypLE | Thermo Fisher Scientific | 12604021 |
| Retinoic acid | Sigma | R2625-50MG |
| LDN-193189 | Stemgent | 04-0074 |
| TBP | Millipore | 565740-1MG |
| ALKi II | Axxora | ALX-270-445-M001 |
| Non-Essential Amino Acids | Gibco | 11140035 |
| FGF7 | R&D Systems | 251-KG-010 |
| STEMdiff™ Pancreatic Progenitor Kit | STEMCELL Technologies | 05120 |
| Wild-type Human iPSC line, from skin tissue of a female donor | HipSci | HPSI0714i-kute_4 |
| Essential 8 Basal Medium | Gibco | A15169-01 |
| Advanced DMEM/F-12 | Gibco | 12634-010 |
| Cell recovery solution | Corning | 354253 |
| Aggrewell™ 400 plates | STEMCELL Technologies | 34411 |
| DMEM 2.8 mM glucose | Gibco | 21885025 |
| DMEM 25 mM glucose | Gibco | 31966021 |
| DAPI | Invitrogen | D1306 |
Organoid expansion medium
| Reagent | Final concentration | Amount |
|---|---|---|
| A83-01 (0.5 mM) | 0.5 nM | 50 μL |
| B-27 (50×) | 1× | 1 mL |
| EGF (50 μg/mL) | 50 ng/mL | 50 μL |
| FGF10 (100 μg/mL) | 50 ng/mL | 50 μL |
| Gastrin 10 μM | 10 mM | 50 μL |
| Noggin (10×) | 1× | 5 mL |
| N-Acetylcysteine (500 mM) | 1.25 mM | 125 μL |
| Nicotinamide (1 M) | 10 mM | 500 μL |
| Penicillin-Streptomycin (100×) | 1× | 500 μL |
| R-Spondin (10×) | 1× | 5 mL |
| Glutamax (100×) | 1× | 500 μL |
| HEPES (100×) | 1× | 500 μL |
| Advanced DMEM/F-12 | N/A | 36.675 mL |
Medium for stage 1 of pancreatic progenitors differentiation to beta cells
| Reagent | Final concentration | Amount |
|---|---|---|
| B-27 (50×) | 0.5× | 100 μL |
| EGF (50 μg/mL) | 50 ng/mL | 10 μL |
| Retinoic acid (10 mM) | 1 μM | 1 μL |
| DMEM 25 mM Glucose | N/A | 9.889 mL |
Medium for stage 2 of pancreatic progenitors differentiation to beta cells
| Reagent | Final concentration | Amount |
|---|---|---|
| B-27 (50×) | 0.5× | 100 μL |
| EGF (50 μg/mL) | 50 ng/mL | 10 μL |
| FGF7 (100 mg/mL) | 50 ng/mL | 5 μL |
| DMEM 25 mM Glucose | N/A | 9.885 mL |
Medium for stage 3 of pancreatic progenitors differentiation to beta cells
| Reagent | Final concentration | Amount |
|---|---|---|
| B-27 (50×) | 0.5× | 100 μL |
| LDN-193189 (5 mM) | 500 nM | 1 μL |
| TBP (300 μM) | 30 nM | 1 μL |
| ALKi II (10 mM) | 1 μM | 1 μL |
| FGF7 (100 mg/mL) | 25 ng/mL | 2.5 μL |
| DMEM 25 mM Glucose | N/A | 9.8945 mL |
Medium for stage 4 of pancreatic progenitors differentiation to beta cells
| Reagent | Final concentration | Amount |
|---|---|---|
| Glutamax (100×) | 1× | 100 μL |
| Non-essential amino acids (100×) | 1× | 100 μL |
| DMEM 2.8 mM Glucose | N/A | 9.8 mL |